GT
SUPN icon

Glenmede Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

Glenmede Trust’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Sell
219,099
-20,084
-8% -$1.02M 0.06% 299
2025
Q4 		$11.9M Buy
+239,183
New +$11.6M 0.06% 292
2025
Q1 		$525K Buy
+16,025
New +$568K ﹤0.01% 895
2023
Q3 		– Sell
-16,946
Closed -$614K – 1362
2023
Q2 		$614K Hold
16,946
– – ﹤0.01% 780
2023
Q1 		$614K Buy
16,946
+1,123
+7% +$43.2K ﹤0.01% 783
2022
Q4 		$564K Buy
15,823
+79
+0.5% +$2.75K ﹤0.01% 807
2022
Q3 		$532K Sell
15,744
-63
-0.4% -$2.05K ﹤0.01% 802
2022
Q2 		$456K Sell
15,807
-274,410
-95% -$7.86M ﹤0.01% 878
2022
Q1 		$9.38M Sell
290,217
-266,712
-48% -$8.18M 0.05% 379
2021
Q4 		$16.2M Sell
556,929
-6,746
-1% -$205K 0.08% 296
2021
Q3 		$15M Sell
563,675
-4,254
-0.7% -$114K 0.08% 284
2021
Q2 		$17.5M Sell
567,929
-1,532
-0.3% -$47K 0.09% 250
2021
Q1 		$14.9M Buy
569,461
+77,727
+16% +$2.17M 0.08% 273
2020
Q4 		$12.4M Sell
491,734
-38,726
-7% -$834K 0.07% 297
2020
Q3 		$11.1M Sell
530,460
-81,504
-13% -$1.85M 0.07% 293
2020
Q2 		$14.5M Sell
611,964
-170,115
-22% -$3.76M 0.09% 263
2020
Q1 		$18.5M Hold
782,079
– – 0.08% 288
2019
Q4 		$18.5M Sell
782,079
-102,635
-12% -$2.49M 0.08% 288
2019
Q3 		$24.3K Sell
884,714
-162,995
-16% -$4.83M 0.11% 246
2019
Q2 		$34.7K Sell
1,047,709
-237,373
-18% -$8.13M 0.15% 192
2019
Q1 		$45K Buy
1,285,082
+80,417
+7% +$2.99M 0.2% 145
2018
Q4 		$40K Buy
1,204,665
+211,182
+21% +$9.08M 0.2% 145
2018
Q3 		$50M Buy
993,483
+340,677
+52% +$16.8M 0.2% 149
2018
Q2 		$39.1M Buy
652,806
+20,012
+3% +$1.04M 0.17% 195
2018
Q1 		$25.2M Hold
632,794
– – 0.11% 270
2017
Q4 		$25.2M Sell
632,794
-88,303
-12% -$3.49M 0.11% 270
2017
Q3 		$28.8M Sell
721,097
-352,238
-33% -$15.2M 0.13% 238
2017
Q2 		$33.5M Hold
1,073,335
– – 0.16% 205
2017
Q1 		$33.5M Sell
1,073,335
-83,537
-7% -$2.24M 0.16% 205
2016
Q4 		$29.2M Sell
1,156,872
-402,740
-26% -$9M 0.16% 225
2016
Q3 		$38.6M Sell
1,559,612
-218,783
-12% -$4.95M 0.22% 133
2016
Q2 		$36.2M Sell
1,778,395
-61,885
-3% -$1.1M 0.22% 141
2016
Q1 		$28.1M Sell
1,840,280
-55,383
-3% -$723K 0.18% 190
2015
Q4 		$25.5M Buy
1,895,663
+702,096
+59% +$10.9M 0.17% 186
2015
Q3 		$16.7M Buy
1,193,567
+1,165,216
+4,110% +$21.7M 0.12% 272
2015
Q2 		$481K Buy
+28,351
New +$404K ﹤0.01% 958

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's SUPN Position: Q1 2026 in Review

Glenmede Trust reduced its Supernus Pharmaceuticals (SUPN) stake by 8.4% in Q1 2026, selling an estimated $1.02M and leaving 219,099 shares worth $11.3M. The position accounts for 0.06% of the portfolio, ranked #299.

Glenmede Trust first reported a position in SUPN in Q2 2015 and has held it in 36 quarters since. The position peaked at $50M in Q3 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Glenmede Trust held 219,099 shares of Supernus Pharmaceuticals worth $11.3M as of Q1 2026.
  • Glenmede Trust sold 20,084 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.02M.
  • Supernus Pharmaceuticals made up 0.06% of Glenmede Trust's portfolio in Q1 2026, its #299 holding.
  • Glenmede Trust first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 36 quarters since.
  • Glenmede Trust's Supernus Pharmaceuticals position peaked at $50M in Q3 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.